KIKA Clinical Solutions Announces Veracity 3.8, Newest Version of its Advanced EDC Solution for Pharmaceutical, Biotechnology an

KIKA Clinical Solutions Announces Veracity 3.8, Newest Version of its Advanced EDC Solution for Pharmaceutical, Biotechnology and Medical Device Clinical Trial Management
BOSTON, Mass and PARIS, France - 28 February 2010 -KIKATM Clinical Solutions announced the availability of VeracityTM 3.8, the latest version of its innovative EDC solution. KIKA is the leading provider of advanced EDC solutions for Clinical Asset ManagementTM for the pharmaceutical, biotechnology and medical device markets.


KIKA CEO Linda Beneze commented, "Veracity 3.8 reflects KIKA's total commitment to providing the industry's most innovative, reliable, flexible EDC technology. Veracity is the only EDC solution that enables sponsors to completely protect, control and maximize their most important clinical trial asset - their data."


Key new functionality in VeracityTM 3.8 includes:


â– Improved Endpoint Adjudication - VeracityTM already leads the EDC industry in endpoint adjudication capabilities. Enhancements in VeracityTM 3.8 provide an even better user experience with new tools that enable advanced endpoint adjudication workflow. The enhancements also facilitate the work of the endpoint processing and review manager, and ensure a faster and easier decision making process.

â– Enhanced Data Audit Trail - Now directly available through the VeracityTM Web client, this new feature version eases the daily tasks of the clinical trial Monitor and Data Manager. The Data Audit Trail tracks and reviews every action performed on the clinical data. It allows global query capabilities on the entire study. It filters and sorts capabilities, displays all useful information (such as author, timestamp, type of actions, old value and new value, hyperlink to the relevant element, etc.).

â– Automated Query - This new extension to the existing module of manual monitoring query saves Monitors time. For a defined criteria (out of ranges values, missing data, etc.) VeracityTM can initiate the manual query process by automatically posting the query to the site. This frees Monitors from having to spend time on this repetitive action.

â– New Language Support - The VeracityTM user interface now is natively supported in Italian and Spanish. Other supported languages are English, French and German.

Several other improvements provide a better end user experience. Additionally, authoring tools enhancements include easier implementation of the signature workflow, the monitoring query workflow, and the SDV workflow.


Announcing New Webinar: "The Next Generation of EDC."

On March 23 KIKA and Accuray Incorporated (Nasdaq: ARAY) will conduct an important Webinar entitled, "The Next Generation of EDC." Attendees will learn how making the monitoring function more efficient improves the quality of the site visit; see how the reporting tools in EDC systems make it easier to see the status of the trial from multiple perspectives; and see how to attach images to the Case Report Form to boost the value of the CRF contents. To register follow the following link: https://kikamedica.webex.com


About KIKA Clinical Solutions

KIKA helps the world's most innovative biopharmaceutical and medical device organizations use advanced EDC solutions to bring much-needed medical solutions to market faster. KIKA's VeracityTM is the leading-edge Web-based clinical trial software platform that delivers Clinical Asset ManagementTM for any size clinical trial. Veracity is customized to meet study needs precisely. It provides unmatched flexibility and customization with advanced EDC including images and online adjudication. Veracity is backed by the industry's most reliable IT infrastructure and a world class Professional Services organization. For more information, visit www.kikaclinicalsolutions.com.


KIKA, Veracity and Clinical Asset Management are trademarks of the KIKA group of companies.


Become a fan of KIKA Clinical Solutions on Facebook and follow KIKAClinical on Twitter.


Media contact: Brenda Nashawaty, [email protected], 617-688-3253

 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.